EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval

Vertex and CRISPR Therapeutics have taken a small step toward a landmark approval, securing European Medicines Agency (EMA) validation of the approval application for their CRISPR-Cas9 candidate.